Haixi Pharma will hold its annual general meeting on 27 May 2026 in Fuzhou, with shareholders asked to vote on 19 resolutions that together signal a comprehensive reshaping of the company’s governance and capital framework.

Key operational and financial items • 2025 Results: Revenue rose 24.79% to RMB582.36 million, while net profit increased 30.09% to RMB177.03 million, translating to earnings of RMB2.55 per share. • Dividend Policy: The Board proposes no profit distribution for 2025, citing the need to preserve capital for future development. • Auditor: Deloitte Touche Tohmatsu is recommended for re-appointment for 2026, with fees capped at HK$1.98 million.

Governance overhaul • Abolishment of the Board of Supervisors is proposed; its duties would transfer to an enhanced Audit Committee under the Board. • Amendments to the Articles of Association and the rules of procedure for shareholders’ and board meetings accompany the governance change. • Full re-election of the nine-member Board is scheduled, comprising four executive, two non-executive and three independent non-executive director candidates.

Capital and financing measures • Management seeks authorisation for up to RMB1.00 billion in new bank credit facilities for 2026 and permission to provide guarantees of up to RMB300 million for wholly owned subsidiary Fuzhou Haixi. • A capital increase for the Hong Kong subsidiary to HK$300.00 million, fully subscribed by the parent company, is up for approval. • Share mandates: the Board requests authority to issue up to 20% of outstanding H Shares (about 15.74 million shares) and to repurchase up to 10% (about 7.87 million shares) over the next year.

Equity incentives • A new 10-year share incentive scheme is on the agenda, with a maximum allocation of 5% of issued H Shares (3.94 million shares). Vesting terms will be set by the Board’s Remuneration and Appraisal Committee. • Share awards may be satisfied through on-market repurchases or cancellation of treasury shares.

Remuneration and other matters • Director allowances for executive and non-executive directors remain nil; independent directors’ annual allowance is set at RMB0.12 million each. • The AGM will also consider renewal of the Deloitte audit mandate, approval of 2025 final accounts and the 2025 ESG report.

Shareholder logistics • The register of members will be closed from 21 May to 27 May 2026. Shareholders on record as of 27 May 2026 may attend and vote. Proxy forms must be lodged 24 hours before the meeting.